Debra Benishek
Psychiatric/Mental Health · Green Bay, WINPI 1164441580
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 599 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,732 and has fallen 95.0% since, to $187 in 2025. Among psychiatric/mental health clinicians in WI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 599 payments — averaging $20.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Alkermes, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Supernus Pharmaceuticals, Inc.$1K
- Lundbeck LLC$1K
- plus $4K from 16 others
What the payments were for
- Food & beverage$11,99599%
- Education$1641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 94 | $1,896 |
| Alkermes, Inc. | 78 | $1,559 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 70 | $1,425 |
| Otsuka America Pharmaceutical, Inc. | 50 | $1,398 |
| Supernus Pharmaceuticals, Inc. | 61 | $1,286 |
| Lundbeck LLC | 75 | $1,088 |
| Neurocrine Biosciences, Inc. | 38 | $997 |
| Corium, LLC | 28 | $513 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $504 |
| Teva Pharmaceuticals USA, Inc. | 7 | $311 |
| Axsome Therapeutics, Inc. | 9 | $233 |
| Sunovion Pharmaceuticals Inc. | 10 | $164 |
| Almatica Pharma LLC | 11 | $148 |
| Biohaven Pharmaceuticals, Inc. | 6 | $121 |
| Eisai Inc. | 6 | $109 |
| Merck | 6 | $94 |
| Bausch Health US, LLC | 5 | $73 |
| Indivior Inc. | 4 | $69 |
| Lilly USA, LLC | 4 | $58 |
| Tris Pharma Inc | 3 | $47 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$891
- VRAYLAR$639
- REXULTI$568
- LYBALVI$480
- INGREZZA$457
- CAPLYTA$356
- QELBREE$336
- ARISTADA INITIO$223
- UBRELVY$212
- Azstarys$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- QULIPTA$109
- Austedo XR$108
How this compares
$12,159 in reported general payments places this provider in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 37 | $294,872 |
| VraylarCariprazine Hcl | 97 | $141,369 |
| Abilify AsimtufiiAripiprazole | 23 | $128,901 |
| Abilify MaintenaAripiprazole | 24 | $71,447 |
| CaplytaLumateperone Tosylate | 36 | $65,376 |
| RexultiBrexpiprazole | 33 | $58,313 |
| AristadaAripiprazole Lauroxil | 13 | $43,897 |
| VyvanseLisdexamfetamine Dimesylate | 57 | $32,898 |
| LybalviOlanzapine/Samidorphan Malate | 19 | $31,638 |
| BelsomraSuvorexant | 39 | $20,459 |
| AzstarysSerdexmethylphen/Dexmethylphen | 32 | $13,429 |
| DayvigoLemborexant | 26 | $8,876 |
| Acamprosate Calcium | 36 | $4,560 |
| Lisdexamfetamine Dimesylate | 13 | $2,828 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 28 | $2,413 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $997 | $294,87237 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Asimtufii, Abilify Maintena, Rexulti | $1,398 | $258,66080 claims |
| AbbVieVraylar | $1,896 | $141,36997 claims |
| Alkermes, Inc.Aristada, Lybalvi | $1,559 | $75,53432 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,425 | $65,37636 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $504 | $32,89857 claims |
| MerckBelsomra | $94 | $20,45939 claims |
| Corium, LLCAzstarys | $513 | $13,42932 claims |
| Eisai Inc.Dayvigo | $109 | $8,87626 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 384 psychiatric/mental health providers in Wisconsin.
Other psychiatric/mental health in Green Bay
- Glenda McConnellGreen Bay$14K
- Amy SchwarzenbartGreen Bay$6K
- Crystal HooymanGreen Bay$4K
- Carolyn DavidsonMilwaukee$46K
- Sherry AleksichMilwaukee$33K
- Bobbi DurstPewaukee$23K
- Ngozi ObioraMilwaukee$19K
- Shalonda MylesBrown Deer$12K
- Victoria McGinleyMilwaukee$9K
- Janet BurnsBrookfield$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.